Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q4 2017 call → NOWe need to determine if management describes that successive engagements of the same kind are coming in at progressively larger size. The question asks: does management convey that the deals, orders, contracts, projects, customers, sites, or programs it is landing NOW are individually bigger, broader, or longer than the ones it was landing for the same offering not long ago, so that each new instance of essentially the same business is worth more to the company than the last? We need to look for any statement from management that indicates escalation in unit size of repeatable business. The transcript covers various divisions: Diagnostics, Breast Health, Surgical, Skeletal, Medical Aesthetics (Cynosure). We need to see if any of these show that the size of individual deals/orders/contracts is increasing. Let's scan the transcript for relevant statements. - In Diagnostics: They talk about Panther systems, shipments, utilization per system. They mention "the average Panther system generated more than $200,000 of assay revenue on a global basis in 2017, nearly a high single-digit increase in utilization per system compared to the prior year." That is about utilization per system, not about the size of individual deals. It's about more revenue per system, but that could be due to more assays per system, not necessarily larger orders. But it's not about the size of new engagements. - In Breast Health: They talk about 3D shipments, record quarter, new products like 3Dimensions and 3D Performance. They mention "we had a record quarter of 3D shipments, again, exceeding the 300 mark, based on strong initial uptake of our recently launched 3Dimensions and 3D Performance systems." That's about number of units shipped, not about the size of each deal. They also mention "we continued to gain market share and our backlog increased." No mention of larger individual orders. - In Surgical: MyoSure sales increasing 17%, NovaSure declining. No mention of deal size. - In Medical Aesthetics (Cynosure): They talk about stabilizing salesforce, new products, but no mention of larger deals. - In the overall discussion, they talk about international growth, but that's about revenue growth, not about individual deal size.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.